Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CymaBay Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CBAY
Nasdaq
8731
https://www.cymabay.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CymaBay Therapeutics Inc
Gilead Sciences Announces Completion of Acquisition of CymaBay
- Mar 22nd, 2024 1:18 pm
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain
- Mar 11th, 2024 6:23 pm
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
- Mar 4th, 2024 1:00 pm
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
- Feb 28th, 2024 11:10 pm
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- Feb 28th, 2024 9:45 pm
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
- Feb 21st, 2024 10:43 pm
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 20th, 2024 9:05 pm
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
- Feb 15th, 2024 1:28 pm
Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY)
- Feb 15th, 2024 8:01 am
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
- Feb 13th, 2024 2:24 pm
CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion
- Feb 12th, 2024 9:15 pm
Stocks to Watch Monday: Diamondback, CymaBay, Gilead, Tod's
- Feb 12th, 2024 5:27 pm
Why Wall Street Was Lukewarm on Gilead’s $4.3 Billion Liver-Drug Deal
- Feb 12th, 2024 5:03 pm
Gilead to Buy Liver Disease Biotech After String of Disappointments
- Feb 12th, 2024 2:57 pm
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal
- Feb 12th, 2024 2:45 pm
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
- Feb 12th, 2024 1:45 pm
Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
- Feb 12th, 2024 1:42 pm
UPDATE 2-Drugmaker Gilead to acquire CymaBay for $4.3 bln
- Feb 12th, 2024 1:38 pm
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
- Feb 12th, 2024 1:30 pm
Gilead to buy CymaBay in $4.3B deal for liver disease drug
- Feb 12th, 2024 11:08 am
Scroll